Trial Profile
A Phase II, Randomised Study to Assess the Pharmacokinetics, Safety and Pharmacodynamics of Single and Repeat Doses of RPL554 Administered by Pressurised Metered Dose Inhaler in Patients With COPD
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Jul 2022
Price :
$35
*
At a glance
- Drugs Ensifentrine (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacokinetics; Therapeutic Use
- Sponsors Verona Pharma
- 20 Jul 2022 According to ClinicalTrials.gov record (NCT04091360), time frame for primary end point has been increased from 12hours to 1 day.
- 13 Oct 2021 According to a Verona Pharma media release, data from this trial will be presented at CHEST Annual Meeting ("CHEST") 2021 .
- 25 Feb 2021 Status changed from recruiting to completed.